lrrk 2

LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.

LRRK2-IN-7 (Compound 25) is a potent, highly selective, CNS-permeable LRRK2 kinase inhibitor with an IC₅₀ of 0.9 nM. LRRK2-IN-7 exhibits more than 1,000-fold selectivity over other kinases, ion channels, and CYP enzymes. LRRK2-IN-7 can be used in research on neurodegenerative diseases.

LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.

LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.

LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).

LRRK2-IN-19 is a PROTAC-targeted protein ligand utilized in the synthesis of PROTAC JH-XII-03-02. JH-XII-03-02 acts as an effective and selective LRRK2 PROTAC degrader, which is applicable for research in Parkinson's disease.

LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).

PROTACLRRK2 Degrader-3 is a PROTACLRRK2 degrader with a DC50 of 0.17 nM. This compound can be utilized in research related to Parkinson's disease and inflammation.

PROTACLRRK2 Degrader-4 is a PROTACLRRK2 degrader with a DC50 of 0.79 nM, employed in research related to Parkinson's disease and inflammation.

LRRK2-IN-6 (compound 22) is an orally active, selective leucine-rich repeat protein kinase 2 (LRRK2) inhibitor with blood-brain barrier permeability, inhibiting GS LRRK2 (IC50: 4.6 μM) and WT LRRK2 (IC50: 49 μM). LRRK2-IN-6 exhibited inhibitory effects on the autophosphorylation of LRRK2 at Ser1292 and Ser925.

LRRK2-IN-5 (compound 25) is an orally active, blood-brain barrier-penetrating, selective leucine-rich repeat protein kinase 2 (LRRK2) inhibitor, effective for GS LRRK2 (IC50: 1.2 μM) and WT LRRK2 (IC50: 16 μM), and can inhibit the autophosphorylation of LRRK2 at Ser1292 and Ser925.

LRRK2-IN-3 is a potent, selective, orally active LRRK2 inhibitor that crosses the blood-brain barrier with an IC50 value of 0.6 nM in hPBMCs. LRRK2-IN-3 can be used to study Parkinson's disease.

LRRK2-IN-4 is a potent, selective, orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor that crosses the blood-brain barrier with an IC50 value of 2.6 nM. LRRK2-IN-3 has shown investigational potential in [Parkinson's disease].

LRRK2-IN-2 is a selective, potent, and orally active LRRK2 inhibitor (IC50: 0.6 nM) that crosses the blood-brain barrier. LRRK2-IN-2 can be used to study Parkinson's disease.

LRRK2/NUAK1/TYK2-IN-1 (compound 226) exhibits inhibitory activity against LRRK2 (Wt), LRRK2 (G2019), TYK2, and NUAK1, demonstrating IC50 values below 10 nM. This compound is useful for research into autoimmune diseases.

LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2 pS935 and 5.2 nM for G2019S-LRRK2 pS1292, holding promise for research into Parkinson's disease [1].

LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].

LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].

LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].

(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.

BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).

Indazole is also called benzpyrazole or isoindazone. Its derivatives exhibit a wide range of biological activities. Indazole and its derivatives can be used in the research of cancer, neurological diseases, cardiovascular diseases, and gastrointestinal diseases.

CZC-25146 (CHEMBL2397014) is an effective, specific and metabolically stable LRRK2 inhibitor with IC50 of 4.76/6.87 nM for wild-type LRRK2(Leucine-rich repeat kinase-2) and G2019S LRRK2, respectively.

JH-II-127 is an oral inhibitor of leucine-rich repeat kinase 2 (LRRK2), targeting WT LRRK2, G2019S LRRK2, and A2016T LRRK2 with IC50 values of 6.6 nM, 2.2 nM, and 47.7 nM, respectively.